UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Personality disorders

Author
Andrew Skodol, MD
Section Editor
Murray B Stein, MD, MPH
Deputy Editor
Richard Hermann, MD

INTRODUCTION

Personality consists of enduring patterns of perceiving, relating to, and thinking about the environment and oneself that are exhibited across numerous social and personal contexts. A personality disorder is diagnosed when personality traits are so inflexible and maladaptive across a wide range of situations that they cause significant distress and impairment of social, occupational, and role functioning. The thinking, displays of emotion, impulsivity, and interpersonal behavior of the individual must deviate markedly from the expectations of the individual's culture in order to qualify as a personality disorder.

Patients with personality disorders can significantly strain the doctor-patient relationship. Clinicians frequently lack training in how to recognize and manage personality disorders.

This topic provides an overview of the personality disorders. Borderline personality disorder and antisocial personality disorder are discussed in detail separately. Challenges to maintaining a therapeutic alliance in patients with personality disorders or traits are also discussed separately. (See "Borderline personality disorder: Epidemiology, clinical features, course, assessment, diagnosis, and differential diagnosis" and "Treatment of borderline personality disorder" and "Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis" and "Treatment of antisocial personality disorder" and "Establishing and maintaining a therapeutic relationship in psychiatric practice".)

CLASSIFICATION

DSM-5 includes 10 personality disorders grouped into three clusters based upon descriptive similarities [1]:

Cluster A characteristics – Individuals may appear odd and eccentric

                                 

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Feb 18 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington 2013.
  2. Huang Y, Kotov R, de Girolamo G, et al. DSM-IV personality disorders in the WHO World Mental Health Surveys. Br J Psychiatry 2009; 195:46.
  3. Grant BF, Chou SP, Goldstein RB, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2008; 69:533.
  4. Zimmerman M, Rothschild L, Chelminski I. The prevalence of DSM-IV personality disorders in psychiatric outpatients. Am J Psychiatry 2005; 162:1911.
  5. Torgersen S. Prevalence, sociodemographics, and functional impairment. In: Essentials of Personality Disorders, Oldham JM, Skodol AE, Bender DS. (Eds), American Psychiatric Publishing, Washington, DC 2009.
  6. Langbehn DR, Pfohl BM, Reynolds S, et al. The Iowa Personality Disorder Screen: development and preliminary validation of a brief screening interview. J Pers Disord 1999; 13:75.
  7. King-Casas B, Sharp C, Lomax-Bream L, et al. The rupture and repair of cooperation in borderline personality disorder. Science 2008; 321:806.
  8. Dumais A, Lesage AD, Boyer R, et al. Psychiatric risk factors for motor vehicle fatalities in young men. Can J Psychiatry 2005; 50:838.
  9. Cadoret RJ, Leve LD, Devor E. Genetics of aggressive and violent behavior. Psychiatr Clin North Am 1997; 20:301.
  10. Caspi A, Begg D, Dickson N, et al. Personality differences predict health-risk behaviors in young adulthood: evidence from a longitudinal study. J Pers Soc Psychol 1997; 73:1052.
  11. Soloff PH, Fabio A. Prospective predictors of suicide attempts in borderline personality disorder at one, two, and two-to-five year follow-up. J Pers Disord 2008; 22:123.
  12. Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry 1999; 56:617.
  13. Zanarini MC, Parachini EA, Frankenburg FR, et al. Sexual relationship difficulties among borderline patients and axis II comparison subjects. J Nerv Ment Dis 2003; 191:479.
  14. Daley SE, Burge D, Hammen C. Borderline personality disorder symptoms as predictors of 4-year romantic relationship dysfunction in young women: addressing issues of specificity. J Abnorm Psychol 2000; 109:451.
  15. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007; 64:830.
  16. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. Br J Psychiatry 2006; 188:13.
  17. Hansen B, Vogel PA, Stiles TC, Götestam KG. Influence of co-morbid generalized anxiety disorder, panic disorder and personality disorders on the outcome of cognitive behavioural treatment of obsessive-compulsive disorder. Cogn Behav Ther 2007; 36:145.
  18. Jansson I, Hesse M, Fridell M. Personality disorder features as predictors of symptoms five years post-treatment. Am J Addict 2008; 17:172.
  19. Gabbard, GO, Simonsen, E. The impact of personality and personality disorders on the treatment of depression. Personal Ment Health 2007; 1:.
  20. Bieling, PJ, Green, SM, Macqueen, G. The impact of personality disorders on treatment outcome in bipolar disorder: A review. Personal Ment Health 2007; 1:2.
  21. Lequesne ER, Hersh RG. Disclosure of a diagnosis of borderline personality disorder. J Psychiatr Pract 2004; 10:170.
  22. Leichsenring F, Leibing E. The effectiveness of psychodynamic therapy and cognitive behavior therapy in the treatment of personality disorders: a meta-analysis. Am J Psychiatry 2003; 160:1223.
  23. Leichsenring F, Rabung S. Effectiveness of long-term psychodynamic psychotherapy: a meta-analysis. JAMA 2008; 300:1551.
  24. Matusiewicz AK, Hopwood CJ, Banducci AN, Lejuez CW. The effectiveness of cognitive behavioral therapy for personality disorders. Psychiatr Clin North Am 2010; 33:657.
  25. Soloff PH. Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin 1998; 62:195.
  26. Herpertz SC, Zanarini M, Schulz CS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry 2007; 8:212.
  27. Binks CA, Fenton M, McCarthy L, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 2006; :CD005653.
  28. Nosè M, Cipriani A, Biancosino B, et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2006; 21:345.
  29. Duggan, C, Huband, N, Smailagic, N, et al. The use of pharmacological treatments for people with personality disorder: A systematic review of randomized controlled trials. Personal Ment Health 2008; 2:119.
  30. Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. Br Med J (Clin Res Ed) 1987; 295:1021.
  31. Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148:1064.
  32. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15:23.
  33. Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002; 159:2048.
  34. Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005; 57:495.
  35. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19:287.
  36. Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005; 162:621.
  37. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63:442.
  38. Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163:833.
  39. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62:849.
  40. Soloff PH, George A, Nathan RS, et al. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986; 43:691.
  41. Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65:104.
  42. Wani RA, Dar MA, Chandel RK, et al. Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study. Neuropsychiatr Dis Treat 2015; 11:685.
  43. Hatzitaskos P, Soldatos CR, Kokkevi A, Stefanis CN. Substance abuse patterns and their association with psychopathology and type of hostility in male patients with borderline and antisocial personality disorder. Compr Psychiatry 1999; 40:278.
  44. Campbell-Sills, L, Stein, MB. Social phobia. In: Cambridge Textbook of Effective Treatments in Psychiatry, Tyrer, P, Silk, KR (Eds), Cambridge University Press, Cambridge 2008. p.563.
  45. Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003; 64:628.
  46. Battaglia M, Fossati A, Torgersen S, et al. A psychometric-genetic study of schizotypal disorder. Schizophr Res 1999; 37:53.
  47. Keefe RS, Silverman JM, Mohs RC, et al. Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. Arch Gen Psychiatry 1997; 54:169.
  48. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry 2004; 161:398.
  49. Vohs JL, Hetrick WP, Kieffaber PD, et al. Visual event-related potentials in schizotypal personality disorder and schizophrenia. J Abnorm Psychol 2008; 117:119.
  50. Raine A. Schizotypal personality: neurodevelopmental and psychosocial trajectories. Annu Rev Clin Psychol 2006; 2:291.
  51. Hazlett EA, Buchsbaum MS, Haznedar MM, et al. Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients. Schizophr Res 2008; 101:111.
  52. Kendler KS. Diagnostic approaches to schizotypal personality disorder: a historical perspective. Schizophr Bull 1985; 11:538.
  53. Coccaro EF. Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects. J Clin Psychiatry 1998; 59 Suppl 1:30.
  54. Goldberg SC, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986; 43:680.